BUZZ-预览：Hims & Hers 下降；关注减肥药物

路透中文

Nov 04

BUZZ-预览：Hims & Hers 下降；关注减肥药物

11月3日 - ** Hims & Hers Health HIMS股价在周一下跌1.2%，因投资者关注用户恢复迹象和减肥药销售势头。

** 分析师预计该公司第三季度营收将增长44%，达到5.802亿美元，每股收益为0.10美元，而去年同期为0.32美元。

** 8 月 4 日发布的上一季度报告显示，性健康业务用户数量下降，而 (link) 从品牌减肥治疗转向低成本减肥治疗导致每用户收入下降。

** 在美国食品和药物管理局取消了允许的大规模复方制剂后，HIMS公司正转向以较小的 "个性化 "剂量生产诺和诺德公司NOVOb.CO的Wegovy减肥药复方制剂。诺和诺德认为大规模个性化生产是非法的。

** HIMS 股价今年以来已上涨约 86%，远远超过标普500指数 .SPX 16% 的涨幅

** 近期股价为预期收益的 60 倍，低于 5 年平均 74 倍的远期市盈率

(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2580248623"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2580248623\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2580248623?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-11-04 00:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580248623","market":"us","top_or_hot":-1,"title":"BUZZ-预览：Hims & Hers 下降；关注减肥药物","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-预览：Hims &amp; Hers 下降；关注减肥药物</title></head><body><p>\n<span>11月3日</span><span> - </span>** Hims &amp; Hers Health <span>HIMS</span>股价在周一下跌1.2%，因投资者关注用户恢复迹象和减肥药销售势头。 </p><p>** 分析师预计该公司第三季度营收将增长44%，达到5.802亿美元，每股收益为0.10美元，而去年同期为0.32美元。 </p><p>** 8 月 4 日发布的上一季度报告显示，性健康业务用户数量下降，而 (<span>link</span>) 从品牌减肥治疗转向低成本减肥治疗导致每用户收入下降。</p><p>** 在<a href=\"https://laohu8.com/S/USFD\">美国食品</a>和药物管理局取消了允许的大规模复方制剂后，HIMS公司正转向以较小的 \"个性化 \"剂量生产<a href=\"https://laohu8.com/S/NVO\">诺和诺德</a>公司<span>NOVOb.CO</span>的Wegovy减肥药复方制剂。诺和诺德认为大规模个性化生产是非法的。</p><p>** HIMS 股价今年以来已上涨约 86%，远远超过标普500指数 <span>.SPX</span> 16% 的涨幅</p><p>** 近期股价为预期收益的 60 倍，低于 5 年平均 74 倍的远期市盈率</p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-预览：Hims & Hers 下降；关注减肥药物</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-预览：Hims & Hers 下降；关注减肥药物\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time\">2025-11-04 00:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-预览：Hims &amp; Hers 下降；关注减肥药物</title></head><body><p>\n<span>11月3日</span><span> - </span>** Hims &amp; Hers Health <span>HIMS</span>股价在周一下跌1.2%，因投资者关注用户恢复迹象和减肥药销售势头。 </p><p>** 分析师预计该公司第三季度营收将增长44%，达到5.802亿美元，每股收益为0.10美元，而去年同期为0.32美元。 </p><p>** 8 月 4 日发布的上一季度报告显示，性健康业务用户数量下降，而 (<span>link</span>) 从品牌减肥治疗转向低成本减肥治疗导致每用户收入下降。</p><p>** 在<a href=\"https://laohu8.com/S/USFD\">美国食品</a>和药物管理局取消了允许的大规模复方制剂后，HIMS公司正转向以较小的 \"个性化 \"剂量生产<a href=\"https://laohu8.com/S/NVO\">诺和诺德</a>公司<span>NOVOb.CO</span>的Wegovy减肥药复方制剂。诺和诺德认为大规模个性化生产是非法的。</p><p>** HIMS 股价今年以来已上涨约 86%，远远超过标普500指数 <span>.SPX</span> 16% 的涨幅</p><p>** 近期股价为预期收益的 60 倍，低于 5 年平均 74 倍的远期市盈率</p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4196","symbol_name":"保健护理服务","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nL4S3WF19A:1","article_id":"2580248623","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580248623","pubTimestamp":1762187622,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"11月3日 - ** Hims & Hers Health HIMS股价在周一下跌1.2%，因投资者关注用户恢复迹象和减肥药销售势头。** 8 月 4 日发布的上一季度报告显示，性健康业务用户数量下降，而  从品牌减肥治疗转向低成本减肥治疗导致每用户收入下降。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4196":"保健护理服务","HIMS":"Hims & Hers Health Inc."},"translate_title":"BUZZ-Preview: Hims & Hers Drop; Focus on weight loss drugs","themeId":"6b43f5868e1a5ac8f736ff2144c2c120","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMS":0.9},"content_text":"BUZZ-预览：Hims & Hers 下降；关注减肥药物\n11月3日 - ** Hims & Hers Health HIMS股价在周一下跌1.2%，因投资者关注用户恢复迹象和减肥药销售势头。 ** 分析师预计该公司第三季度营收将增长44%，达到5.802亿美元，每股收益为0.10美元，而去年同期为0.32美元。 ** 8 月 4 日发布的上一季度报告显示，性健康业务用户数量下降，而 (link) 从品牌减肥治疗转向低成本减肥治疗导致每用户收入下降。** 在美国食品和药物管理局取消了允许的大规模复方制剂后，HIMS公司正转向以较小的 \"个性化 \"剂量生产诺和诺德公司NOVOb.CO的Wegovy减肥药复方制剂。诺和诺德认为大规模个性化生产是非法的。** HIMS 股价今年以来已上涨约 86%，远远超过标普500指数 .SPX 16% 的涨幅** 近期股价为预期收益的 60 倍，低于 5 年平均 74 倍的远期市盈率(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}